News stories about Agile Therapeutics (NASDAQ:AGRX) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Agile Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 46.6743225103329 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for … – Nasdaq (nasdaq.com)
- Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for … – Markets Insider (markets.businessinsider.com)
- Agile Therapeutics (AGRX) Presents At 6th Annual Liolios Gateway Conference – Slideshow (seekingalpha.com)
- Bristol-Myers Squibb Company (BMY) is at $59.87 per share and Agile Therapeutics, Inc. (AGRX) is listed at $3.34 – Stocks Gallery (stocksgallery.com)
- Agile Therapeutics to Present Additional Phase 3 Data at the 73rd Annual Congress of the American Society for … – GlobeNewswire (press release) (globenewswire.com)
A number of analysts recently issued reports on AGRX shares. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a report on Wednesday, June 14th. Janney Montgomery Scott reissued a “buy” rating and set a $13.00 price target on shares of Agile Therapeutics in a report on Thursday, September 7th. HC Wainwright started coverage on shares of Agile Therapeutics in a report on Wednesday, July 19th. They set a “buy” rating and a $10.00 price target on the stock. Royal Bank Of Canada set a $8.00 price target on shares of Agile Therapeutics and gave the stock a “buy” rating in a report on Sunday, July 16th. Finally, ValuEngine raised shares of Agile Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, July 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $8.75.
Shares of Agile Therapeutics (NASDAQ AGRX) traded up 0.85% during midday trading on Wednesday, hitting $3.56. 73,599 shares of the stock were exchanged. Agile Therapeutics has a 12-month low of $1.82 and a 12-month high of $7.95. The firm’s market cap is $102.55 million. The firm has a 50-day moving average price of $3.69 and a 200 day moving average price of $3.42.
Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings data on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. During the same quarter in the previous year, the business earned ($0.29) earnings per share. Analysts predict that Agile Therapeutics will post ($1.03) earnings per share for the current fiscal year.
In other Agile Therapeutics news, Chairman Alfred Altomari acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The shares were acquired at an average cost of $3.34 per share, for a total transaction of $33,400.00. Following the transaction, the chairman now directly owns 161,587 shares of the company’s stock, valued at $539,700.58. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.50% of the stock is owned by insiders.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.